LDL oxidation by platelets propagates platelet activation via an oxidative stress-mediated mechanism
- PMID: 25238217
- DOI: 10.1016/j.atherosclerosis.2014.08.041
LDL oxidation by platelets propagates platelet activation via an oxidative stress-mediated mechanism
Abstract
Objectives: Platelets generate oxidized LDL (ox-LDL) via NOX2-derived oxidative stress. We investigated if once generated by activated platelets ox-LDL can propagate platelet activation.
Methods: Experiments were performed in platelets from healthy subjects (HS), hyper-cholesterolemic patients and patients with NOX2 hereditary deficiency.
Results: Agonist-stimulated platelets from HS added with LDL were associated with a dose-dependent increase of reactive oxidant species and ox-LDL. Agonist-stimulated platelets from HS added with a fixed dose of LDL (57.14 μmol/L) or added with homogenized human atherosclerotic plaque showed enhanced ox-LDL formation (approximately +50% and +30% respectively), which was lowered by a NOX2 inhibitor (approximately -35% and -25% respectively). Compared to HS, ox-LDL production was more pronounced in agonist-stimulated platelet rich plasma (PRP) from hyper-cholesterolemic patients but was almost absent in PRP from NOX2-deficient patients. Platelet aggregation and 8-iso-PGF2α-ΙΙΙ formation increased in LDL-treated washed platelets (+42% and +53% respectively) and PRP (+31% and +53% respectively). Also, LDL enhanced platelet-dependent thrombosis at arterial shear rate (+33%) but did not affect platelet activation in NOX2-deficient patients. Platelet activation by LDL was significantly inhibited by CD36 or LOX1 blocking peptides, two ox-LDL receptor antagonists, or by a NOX2 inhibitor. LDL-added platelets showed increased p38MAPK (+59%) and PKC (+51%) phosphorylation, p47(phox) translocation to platelet membrane (+34%) and NOX2 activation (+30%), which were inhibited by ox-LDL receptor antagonists.
Conclusion: Platelets oxidize LDL, which in turn amplify platelet activation via specific ox-LDL receptors; both effects are mediated by NOX2 activation.
Keywords: Atherosclerosis; NADPH oxidase; Oxidative stress; ox-LDL.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
LDL-platelet interaction under oxidative stress induces macrophage foam cell formation.Thromb Haemost. 1995 Jul;74(1):560-4. Thromb Haemost. 1995. PMID: 8578524 Review.
-
HIV-1 induces in vivo platelet activation by enhancing platelet NOX2 activity.J Infect. 2015 Jun;70(6):651-8. doi: 10.1016/j.jinf.2015.01.005. Epub 2015 Jan 15. J Infect. 2015. PMID: 25597822
-
LDL are oxidatively modified by platelets via GP91(phox) and accumulate in human monocytes.FASEB J. 2007 Mar;21(3):927-34. doi: 10.1096/fj.06-6908com. Epub 2006 Dec 27. FASEB J. 2007. PMID: 17194695
-
Differential Roles of the NADPH-Oxidase 1 and 2 in Platelet Activation and Thrombosis.Arterioscler Thromb Vasc Biol. 2016 May;36(5):846-54. doi: 10.1161/ATVBAHA.116.307308. Epub 2016 Mar 17. Arterioscler Thromb Vasc Biol. 2016. PMID: 26988594 Free PMC article.
-
Platelet NOX, a novel target for anti-thrombotic treatment.Thromb Haemost. 2014 May 5;111(5):817-23. doi: 10.1160/TH13-10-0818. Epub 2014 Jan 9. Thromb Haemost. 2014. PMID: 24402688 Review.
Cited by
-
PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation.Front Cardiovasc Med. 2021 Mar 23;8:639727. doi: 10.3389/fcvm.2021.639727. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 33834043 Free PMC article. Review.
-
LOX-1: Implications in atherosclerosis and myocardial ischemia.EXCLI J. 2022 Jan 13;21:273-278. doi: 10.17179/excli2021-4532. eCollection 2022. EXCLI J. 2022. PMID: 35368459 Free PMC article. Review.
-
Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways.Int J Mol Sci. 2021 Jul 3;22(13):7193. doi: 10.3390/ijms22137193. Int J Mol Sci. 2021. PMID: 34281247 Free PMC article.
-
The Impact of Patient Characteristics and Antiplatelet Regimes on Clot Microstructure in Patients Treated for ST Elevation Myocardial Infarction: Clot Microstructure can Evaluate Therapeutic Efficacy.Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296221131563. doi: 10.1177/10760296221131563. Clin Appl Thromb Hemost. 2023. PMID: 36994631 Free PMC article.
-
Role of PCSK9 inhibitors in venous thromboembolism: current evidence and unmet clinical needs.Eur Heart J Cardiovasc Pharmacother. 2025 Jan 11;10(8):719-724. doi: 10.1093/ehjcvp/pvae076. Eur Heart J Cardiovasc Pharmacother. 2025. PMID: 39406397 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous